Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 1% Improvement Relative Risk Ventilation 34% Recovery 6% Hospitalization time 4% Abd-Elsalam et al. Zinc for COVID-19 RCT LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? RCT 191 patients in Egypt Trial underpowered for serious outcomes Abd-Elsalam et al., Biological Trace Element Res.., doi:10.1007/s12011-020-02512-1 Favors zinc Favors control
Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1
Abd-Elsalam et al., Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial, Biological Trace Element Research, doi:10.1007/s12011-020-02512-1
Nov 2020   Source   PDF  
  All Studies   Meta
191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference. No information on baseline zinc values was recorded. Egypt has a low rate of zinc deficiency so supplementation may be less likely to be helpful [, (B)]. For several issues with this trial, see []. This study is excluded in the after exclusion results of meta analysis: multiple potential data reliability issues.
risk of death, 1.0% lower, RR 0.99, p = 0.99, treatment 5 of 96 (5.2%), control 5 of 95 (5.3%), NNT 1824.
risk of mechanical ventilation, 34.0% lower, RR 0.66, p = 0.54, treatment 4 of 96 (4.2%), control 6 of 95 (6.3%), NNT 47.
risk of no recovery, 5.8% lower, RR 0.94, p = 0.97, treatment 20 of 96 (20.8%), control 21 of 95 (22.1%), NNT 79.
hospitalization time, 3.6% lower, relative time 0.96, p = 0.55, treatment 96, control 95.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abd-Elsalam et al., 29 Nov 2020, Randomized Controlled Trial, Egypt, peer-reviewed, 10 authors, data issues, see notes.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Biological Trace Element Research (2021) 199:3642–3646 Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial Sherief Abd-Elsalam 1 & Shaimaa Soliman 2 & Eslam Saber Esmail 1 & Mai Khalaf 1 & Ehab F. Mostafa 3 & Mohammed A. Medhat 3 & Ossama Ashraf Ahmed 4 & Mohamed Samir Abd El Ghafar 5 & Mohamed Alboraie 6 & Sahar M. Hassany 3 Received: 1 September 2020 / Accepted: 23 November 2020 / Published online: 27 November 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020 Abstract No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients’ mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19. Identifier: NCT04447534 Keywords Zinc . Chloroquine . Antioxidants . COVID 19 . Treatment
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop